Echinocandins in the management of invasive fungal infections, part 1
- 15 September 2006
- journal article
- review article
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 63 (18) , 1693-1703
- https://doi.org/10.2146/ajhp050464.p1
Abstract
Purpose. The chemistry, pharmacology, spectrum of activity, resistance, pharmacokinetics, pharmacodynamics, clinical efficacy, adverse effiects, drug interactions, dosage and administration, cost, and place in therapy of echinocandins are reviewed.Keywords
This publication has 48 references indexed in Scilit:
- Specific Substitutions in the Echinocandin Target Fks1p Account for Reduced Susceptibility of Rare Laboratory and Clinical Candida sp. IsolatesAntimicrobial Agents and Chemotherapy, 2005
- A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasisAlimentary Pharmacology & Therapeutics, 2005
- Pharmacokinetics/pharmacodynamics of echinocandinsEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- A Randomized, Double-Blind Trial of Anidulafungin versus Fluconazole for the Treatment of Esophageal CandidiasisClinical Infectious Diseases, 2004
- A Multicenter, Open-Label Clinical Study of Micafungin (FK463) in the Treatment of Deep-seated Mycosis in JapanScandinavian Journal of Infectious Diseases, 2004
- In Vitro Activity of Anidulafungin against Selected Clinically Important Mold IsolatesAntimicrobial Agents and Chemotherapy, 2004
- Disposition of Caspofungin: Role of Distribution in Determining Pharmacokinetics in PlasmaAntimicrobial Agents and Chemotherapy, 2004
- Echinocandin antifungal drugsThe Lancet, 2003
- Overexpression of Sbe2p, a Golgi Protein, Results in Resistance to Caspofungin in Saccharomyces cerevisiaeAntimicrobial Agents and Chemotherapy, 2002
- The natural history of esophageal candidiasis after successful treatment in patients with AIDSGastroenterology, 1994